
REGULATORY
12 Mar 2026
Medicare launches a temporary program giving eligible patients early, subsidized access to GLP-1 obesity drugs

INNOVATION
6 Mar 2026
Altimmune confirms a 2026 Phase 3 launch for pemvidutide, backed by FDA Breakthrough Therapy status and $340M in capital

TECHNOLOGY
4 Mar 2026
AI uncovers fat-burning genes that could inspire a new class of obesity drugs targeting metabolism, not appetite

INSIGHTS
2 Mar 2026
AI drug developers face mounting pressure to turn machine learning breakthroughs into real clinical results

INNOVATION
25 Feb 2026
Alliance uses AI and clinical data to target IBD, dermatitis, and MS while cutting R&D risks

PARTNERSHIPS
24 Feb 2026
US drugmaker expands Nimbus alliance to pursue oral therapy as analysts forecast $100bn market for weight-loss medicines
By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.